The primary mode of acquisition is percutaneous exposure to blood, including sharing of injection paraphernalia and a historically contaminated blood supply, which led to a maximum prevalence in the cohort of individuals born from 1945 to 1965. 2, 3 Previously, treatment of HCV genotype 1 required as long as 48 weeks, with cure rates of 40% to 70% in patients with HCV monoinfection. 1 With the introduction of HCV nucleotide analogue nonstructural protein 5A and B inhibitors, such as ledipasvir, ombitasvir, dasabuvir, and sofosbuvir, treatment duration has decreased for most patients to 12 weeks or less, with reduced toxic effects by the exclusion of interferon and often with the exclusion of ribavirin. 4 The cure rate with the new therapies generally exceeds 90% and reaches 100% in some subgroups in clinical trials. [4] [5] [6] [7] The new drugs cost $1000 per day or more based on the wholesale acquisition price. 8 Such costs are prohibitive for many patients and health care systems. Health care professionals may therefore resort to less effective drugs or wait for disease progression before initiating treatment.
Recent cost-effectiveness studies show that treatment with new therapies compared with older drugs is cost-effective for patients with HCV genotype 1, with a net cost per qualityadjusted life-year (QALY) ranging from $10 000 to $30 000. 9, 10 These studies, however, do not analyze the implications of treatment at various stages of liver fibrosis. Thus, the optimal timing of treatment is unknown.
Despite clinical practice guidelines recommending the new antiviral drugs, some payers require a higher level of fibrosis before authorizing treatment.
11-15 Untreated chronic HCV infection can progress with increasing fibrosis, reaching cirrhosis in 20% to 30% of patients, and related liver complications, including premature death, in a smaller subset. [16] [17] [18] Even with viral elimination, some patients may experience disease progression. Earlier treatment might provide important clinical and cost benefits. The objective of this study was to determine the most cost-effective liver fibrosis stage at which to initiate treatment with direct-acting antiviral agents in US treatment-naive patients with HCV genotype 1 infection and was based on commonly accepted thresholds. We present an analysis of a fixed-dose combination of sofosbuvir and ledipasvir (hereinafter, sofosbuvir-ledipasvir). Other regimens are analyzed in eTable 1 in the Supplement.
Methods

Model Overview
We constructed a decision-analytic model of HCV to examine the clinical outcomes and costs of treatment initiated at different disease stages. 
Treatment Characteristics
The model considered therapies for HCV genotype 1 infection by regimens and doses approved by the US Food and Drug Administration. 19 The goal of treatment is an undetectable serum level of HCV RNA 12 weeks after completion of therapy, also termed a sustained virologic response (SVR). 20 The likelihood of an SVR and treatment discontinuation were determined by meta-analyses of phases 2 and 3 clinical trials stratified by the presence or absence of cirrhosis. 15 Discontinuation of therapy was calculated as patient withdrawal from clinical trials for any reason, with an intent-to-treat approach. The discontinuation and SVR rates were subjected to sensitivity analyses. We present results for sofosbuvir-ledipasvir treatment for 8 or 12 weeks. Duration of sofosbuvir-ledipasvir treatment can be 8 weeks if the baseline viral load is less than 6 million IU/mL with no cirrhosis. Thus 67% of the patients with fibrosis stages F0 to F3 received 8 weeks of treatment and 33% received 12 weeks; all patients with stage F4 received 12 weeks of treatment.
15 These proportions were varied in sensitivity analyses. We modeled 6 other HCV treatment regimens (eTable 1 in the Supplement).
Natural History of Chronic HCV
Chronic HCV progression through increasingly severe liver fibrosis is classified with fibrosis scores F0 to F4 (eTable 1 and eFigure 1 in the Supplement). We used these scores and major liver complications to define Markov model disease states (eFigures 1-3 in the Supplement). Transition probabilities between states are based on our review of the published literature. We validated this natural history model by demonstrating correspondence with empirical data on cirrhosis incidence and prior modeling (eTable 2 and eFigure 4 in the Supplement). 
Costs and Use of Health Care Resources
We adopted a societal perspective, including all direct medical costs for HCV management and therapy. Our intent is to portray societal costs, as approximated by the cost of care sources on which we rely. For unit costs based on reimbursement, the omission of small patient contributions slightly underestimates total costs (a synopsis of each study is provided in the eMethods in the Supplement). Owing to the imprecision of unit cost inputs and the greater uncertainty introduced by estimated rates of patients under current care and use of health care resources, we examined wide ranges of costs in our sensitivity analyses. Costs are in US dollars adjusted to 2014 using the medical component of the US Consumer Price Index.
40
Costs of drugs were determined using the wholesale acquisition price from Red Book Online 8 in February 2015 and varied widely in sensitivity analyses. In a scenario analysis, drug costs were reduced by 46%, reflecting recent price reductions announced by Gilead Sciences, Inc.
41
Annual health care costs associated with a diagnosis of chronic HCV were determined by adapting published empirical data to our cohort of individuals with known chronic HCV.
42-44 Pre-SVR costs ($810 for stages F0-F2, $2150 for stage F3, and $2575 for stage F4) were based on costs from a managed care database that were adjusted for the proportion of known chronic HCV cases estimated to receive health care.
44,45
Post-SVR costs for stages F0 to F4 were estimated at 50% lower by taking the midpoint of 2 pre-SVR vs post-SVR cost ratios derived from medical care payment databases in the United States and the United Kingdom. 42, 46 The model accounted for costs of HCV genotyping, fibrosis staging, and therapy monitoring, including clinic visits, blood and hepatic tests, and HCV RNA quantification. These costs were determined using the Medicare reimbursement schedule and published literature. [47] [48] [49] The frequency of monitoring visits and tests was based on HCV treatment guidelines and clinical judgment.
11,50
The costs of management of adverse effects were estimated using the frequency of common and serious adverse effects (determined using regimen-specific meta-analysis of clinical trials). We applied the published costs of similar adverse events.
15,51
Health State Utility Values 
Model Outcomes
The model produces discounted lifetime QALYs and direct medical costs for each strategy. It then calculates incremental cost-effectiveness ratios (ICERs) as the ratio of the difference in costs between treatment strategies divided by the difference in QALYs. A policy producing an ICER of $150 000 per QALY or less was considered cost-effective; a policy producing an ICER of $50 000 per QALY was considered highly costeffective. The model was constructed using TreeAge Pro 2014, 52 and Excel software 53 was used to analyze the data.
Sensitivity Analysis
We conducted 1-way sensitivity analysis on each variable to determine effects on the ICER and 2-way sensitivity analysis on selected variables. The aggregate uncertainty from multiple inputs was quantified via probabilistic sensitivity analysis using uniform distributions. The range in input values was determined by 95% CIs from primary literature sources or meta-
Results
Base Case Results
We present results only for 8 and 12 weeks of sofosbuvirledipasvir treatment. Results for other regimens are similar and are presented in eTable 13 in the Supplement.
Treatment of All Stages vs Stages F3 and F4
For sofosbuvir-ledipasvir treatment for 8 and 12 weeks, treating all stages of fibrosis compared with treating stages F3 and F4 produced a QALY gain of 0.73 (Table) owing to a higher health state utility value after SVR in early fibrosis (69% of the QALY benefit) and to averted liver complications and death ( Figure 1 and eTable 14 in the Supplement; 31% of the QALY benefit). Treating all stages of fibrosis compared with treating stages F3 and F4 increases drug costs by $33 721. An SVR lowers lifetime health care costs by about $5000, resulting in net increased costs of $28 899 for sofosbuvir-ledipasvir treatment (Table and eTable (Table) .
Treatment by Fibrosis Stage
Sofosbuvir-ledipasvir treatment at earlier stages of fibrosis results in a gain in QALYs (Table) Percentages were calculated per 100 000 treated patients using 100 000 Monte Carlo simulations. For every 100 000 patients treated (treatment naive, prevalent cohort aged 60 years), the percentage of the advanced liver disease cases that could be averted by treating all stages with combined sofosbuvir and ledipasvir for 8 or 12 weeks compared with treating stages F3 and F4 only are shown. By treating all stages of fibrosis vs waiting to treat at stages F3 and F4, the percentage of averted cases of liver transplant, decompensated cirrhosis, hepatocellular carcinoma, and liver death are 26%, 17%, 27%, and 25%, respectively. Fibrosis is measured using the METAVIR stages (described in the Model Overview subsection of the Methods section).
Deterministic Sensitivity Analyses
The inputs to which the ICER for treating all fibrosis stages compared with treating stages F3 and F4 are most sensitive are cohort age and drug cost, with much lower sensitivity to discount rate, utility values in stages F1 and F2 (without SVR), and proportion of patients with disease regression to healthier fibrosis stages (Figure 2) . For age, use of a cohort age of 50 years (vs 60 in the base-case analysis) produced the more favorable ICER or $25 443 per QALY gained. At 20 years of age, the ICER is $999 per QALY gained owing to a high likelihood of progression without SVR. At 70 years of age, the ICER is $118 889 per QALY gained owing to the reduced likelihood of untreated chronic HCV causing death. For age analyses, agedependent fibrosis progression probabilities were used with base-case fibrosis prevalence (eTable 4 in the Supplement). For drug prices, we referenced a recent announcement by Gilead Sciences, Inc (the manufacturer of sofosbuvir-ledipasvir), of a mean price discount to 46%. 41 
Probabilistic Sensitivity Analysis
Monte Carlo simulations are shown in Figure 3 as the likelihood of a timing option to be considered cost-effective at different willingness-to-pay thresholds. At a willingness-to-pay threshold of $50 000 per QALY, treating all stages is costeffective in 74% of simulations. This proportion rises to 96% at a willingness-to-pay threshold of $150 000 per QALY. Probabilistic sensitivity analyses for other regimens are available in eTable 13 and eFigures 9 to 12 in the Supplement.
Budget Impact Analysis
A prior analysis determined 1.32 million treatment-naive persons in the United States would be aware of their HCV infection status by 2014, with an additional 510 000 identified by 2019, for a total of 1.83 million patients. 9, 54 Assuming that 75% of these patients have HCV genotype 1 (1.37 million), we determined the total cost of drugs required to treat 25%, 50%, 75%, and 100% of these patients during the next 5 years in our budget impact analysis (full details are available in eTable 15 in the Supplement). Figure 4 shows the drug costs of sofosbuvir-ledipasvir treatment. If 50% of eligible patients with HCV genotype 1 (ie, 686 000 patients) are treated regardless of fi- brosis stage during the next 5 years, the estimated unadjusted treatment costs are $53 billion. With the 46% reduction in drug prices discussed above, the cost decreases to $29 billion. Alternatively, if 50% of these patients are treated at stages F3 and F4 during the next 5 years, the costs are $30 billion with sofosbuvir-ledipasvir treatment and $16 billion with a 46% decrease in drug prices. Figure 4 depicts the savings in lifetime health care costs exclusive of drug costs gained by treating all stages compared with treating stages F3 and F4, which is $3.3 billion with sofosbuvir-ledipasvir treatment.
Discussion
The new HCV interferon-free therapies offer potentially huge individual and societal benefits but at a large cost. Health plans and health systems concerned about costs frequently require evidence of advanced liver fibrosis before authorizing the new therapies. 11-14 We herein examined the health impact, cost, and cost-effectiveness of earlier treatment. Although early treatment with sofosbuvir-ledipasvir is expensive, the net cost is substantially lower owing to savings in medical care and the likelihood of later treatment with a delayed treatment policy. Furthermore, we found substantial short-and long-term health gains. Thus, for sofosbuvirledipasvir treatment, treating patients at all fibrosis stages compared with waiting for advanced fibrosis is cost-effective (<$50 000 per QALY gained). A detailed analysis of timing of therapy by fibrosis stage shows that treating the disease at as early as stage F1 is cost-effective (ICERs of $50 000-$150 000 per QALY gained) and less than $50 000 per QALY gained when treatment is initiated at stage F2 vs stage F3. The ICER is lower when treatment is initiated at stage F3 compared with waiting for cirrhosis (stage F4). Results are similar for treatment with other new antiviral regimens.
Although the new therapies promise a high SVR, their longterm effects on clinical outcomes are not yet known. Sustained virologic response, a surrogate marker, may not lead to better long-term health outcomes with new treatments. Past studies with older regimens, however, have shown that achieving SVR can result in positive, long-term clinical benefits for patients.
55-60 A 2011 systematic review 61 found that achieving SVR can reduce liver-related mortality, incidence of hepatocellular carcinoma, and decompensation and foster regression of fibrosis and cirrhosis. For budgetary considerations, if only 50% of eligible patients with HCV genotype 1 were to be treated with sofosbuvirledipasvir during the next 5 years, the cost of drugs in the United States would be $53 billion at current prices. Many payers negotiate prices, as has been seen with exclusivity deals with drug manufacturers. [62] [63] [64] [65] If a mean 46% reduction in drug prices occurred, the cost of treating 50% of patients with HCV genotype 1 during the next 5 years could be as high as $29 billion, partly offset by $3 billion in savings in the management of chronic HCV and advanced liver disease. Our model has several assumptions and limitations. First, we assumed that patients who achieve SVR have no risk for reinfection with HCV, thus tending to overestimate costeffectiveness. Second, the model does not consider benefits for patients who receive therapy but do not achieve SVR. Third, Results of 10 000 Monte Carlo simulations (probabilistic sensitivity analysis) in which all input variables are varied simultaneously based on the listed ranges. The graph shows the percentage of simulations in which treating all patients (regardless of fibrosis stage) with sofosbuvir-ledipasvir for 8 or 12 weeks was considered cost-effective compared with treating only patients who reached fibrosis stages F3 and F4, depending on the willingness-to-pay (WTP) threshold. As the WTP increases (from left to right on the x-axis), the percentage of simulations resulting in treatment of all patients being cost-effective also increases. For example, for treatment at a WTP of $50 000 per quality-adjusted life-year (QALY), treating all patients is cost-effective in 74%; at a WTP of $150 000 per QALY, treating all patients is cost-effective in 96%. Fibrosis is measured using the METAVIR stages (described in the Model Overview subsection of the Methods section). Treat all (drug costs)
Treat at stages F3 and F4 (drug costs)
Health care cost offsets
The figure shows total drug costs for treating 25%, 50%, 75%, and 100% of the 1.37 million treatment-naive patients (identified during the next 5 years) with combined sofosbuvir and ledipasvir for 8 or 12 weeks. The analyses are subcategorized by treating all patients (treatment regardless of fibrosis stage) and treating only patients who reached stages F3 and F4. Offsets in savings in lifetime health care costs (exclusive of drug costs) achieved by treating all patients vs treating those with stages F3 and F4 are also shown. Fibrosis is measured using the METAVIR stages (described in the Model Overview subsection of the Methods section).
the model does not consider the reduction in HCV transmission to seronegative individuals as a consequence of successful therapy. These latter 2 assumptions would underestimate the societal and economic benefits of treatment. Fourth, the model did not consider extended treatment for patients with slow responses or the repeated treatment of patients who do not achieve SVR. Additional therapy would add to the costs of treatment and possibly improve efficacy. Fifth, the model uses aggregated annualized transition probabilities to simulate progression from one clinical state to the next, adjusted for age but not for other individual traits. This approach focuses the overall simulation on population-level natural history. Individual heterogeneity in chronic hepatitis C virus progression is represented by varying progression rates in sensitivity analyses. Sixth, the analysis took into account only direct medical costs, omitting potential gains in productivity. Seventh, the model considered only patients monoinfected with HCV, excluding coinfections with hepatitis B virus and human immunodeficiency virus.
Eighth, we used meta-analyses of clinical trials to determine SVR and discontinuation rates. The point estimates may differ from those of published phases 2 and 3 trials. We used an intent-to-treat analysis to determine discontinuation rates, and our values may therefore be higher than other estimates. Point estimates from clinical trials may not represent realworld results, which can be lower for SVR and higher for discontinuation rates. 66, 67 However, our meta-analysis 95% CIs are wide, which allowed us to test SVRs across a wide range in sensitivity analyses. Ninth, we had imperfect cost data. Costs for HCV care, treatment, and adverse effects are sparsely reported. We attempted to portray societal costs, as measured by the source studies. Our priority in selecting cost sources was addressing a scope of care closely aligned with our model categories. Owing to limited data, we never had to choose between multiple sources for the same data point; therefore, we had to rely on the relevant source's costing methods (eMethods in the Supplement). However, the most challenging aspect of costing was extrapolating from very good costing data for the identified population receiving care (defined by ≥2 HCV codes in a year, thus likely omitting clinically healthy individuals with HCV) to the broader population receiving care and the even larger infected population. The future cost of new HCV therapy is also a major unknown. Because of these various uncertainties, we carefully explored the implications of different cost estimates for the cost-effectiveness outcomes via sensitivity analyses of the cost inputs and of the discount rate that affects the evaluation of future expected costs.
Finally, this model did not simulate changing drug costs over time and how that would affect the cost-effectiveness of early treatment. Market or political forces may result in significantly decreased drug costs in the next several years, and a subset of patients, given the slow progression of HCV, may be treated at a lower cost without a risk for serious clinical progression. These possibilities would make early treatment less cost-effective. However, as in the case of therapies for multiple sclerosis and insulin, the cost of drugs may increase despite being on the market for a number of years and despite new entrants.
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Conclusions
This analysis suggests that treatment with new HCV drugs is cost-effective when started with any evidence of fibrosis (stage F1). Because of the investment required for these drugs, budgetary constraints on health systems typically restrict access to insured patients until they experience higher levels of liver damage or failure of older treatments, and uninsured patients would be unable to receive treatment without patient assistance programs. A reduction in the price will improve costeffectiveness and increase affordability and access.
